These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 15131469)

  • 1. Immunologic changes during unplanned treatment interruptions of highly active antiretroviral therapy in children with human immunodeficiency virus type 1 infection.
    Gibb DM; Duong T; Leclezio VA; Walker AS; Verweel G; Dunn DT;
    Pediatr Infect Dis J; 2004 May; 23(5):446-50. PubMed ID: 15131469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.
    Verweel G; van Rossum AM; Hartwig NG; Wolfs TF; Scherpbier HJ; de Groot R
    Pediatrics; 2002 Feb; 109(2):E25. PubMed ID: 11826235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Highly active antiretroviral therapy (HAART) retreatment in patients on CD4-guided therapy achieved similar virologic suppression compared with patients on continuous HAART: the HIV Netherlands Australia Thailand Research Collaboration 001.4 study.
    Ananworanich J; Siangphoe U; Hill A; Cardiello P; Apateerapong W; Hirschel B; Mahanontharit A; Ubolyam S; Cooper D; Phanuphak P; Ruxrungtham K
    J Acquir Immune Defic Syndr; 2005 Aug; 39(5):523-9. PubMed ID: 16044002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response to highly active antiretroviral therapy varies with age: the UK and Ireland Collaborative HIV Paediatric Study.
    Walker AS; Doerholt K; Sharland M; Gibb DM;
    AIDS; 2004 Sep; 18(14):1915-24. PubMed ID: 15353977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treatment interruption in 30 HIV-infected patients with successful viral suppression under highly active antiretroviral treatment].
    Pavie J; Porcher R; Fournier S; André F; Tournoux C; Palmer P; Rabian C; Jean-Michel M
    Presse Med; 2005 Jun; 34(10 Suppl):1S8-13. PubMed ID: 16025661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discontinuation of antiretroviral therapy in patients with chronic HIV infection: clinical, virologic, and immunologic consequences.
    Mata RC; Viciana P; de Alarcón A; López-Cortés LF; Gómez-Vera J; Trastoy M; Cisneros JM
    AIDS Patient Care STDS; 2005 Sep; 19(9):550-62. PubMed ID: 16164382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A prospective trial of structured treatment interruptions in human immunodeficiency virus infection.
    Fagard C; Oxenius A; Günthard H; Garcia F; Le Braz M; Mestre G; Battegay M; Furrer H; Vernazza P; Bernasconi E; Telenti A; Weber R; Leduc D; Yerly S; Price D; Dawson SJ; Klimkait T; Perneger TV; McLean A; Clotet B; Gatell JM; Perrin L; Plana M; Phillips R; Hirschel B;
    Arch Intern Med; 2003 May; 163(10):1220-6. PubMed ID: 12767960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response to planned treatment interruptions in HIV infection varies across childhood.
    Paediatric European Network for Treatment of AIDS
    AIDS; 2010 Jan; 24(2):231-41. PubMed ID: 20010073
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response to highly active antiretroviral therapy according to duration of HIV infection.
    Pezzotti P; Pappagallo M; Phillips AN; Boros S; Valdarchi C; Sinicco A; Zaccarelli M; Rezza G;
    J Acquir Immune Defic Syndr; 2001 Apr; 26(5):473-9. PubMed ID: 11391168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.
    Steingrover R; Pogány K; Fernandez Garcia E; Jurriaans S; Brinkman K; Schuitemaker H; Miedema F; Lange JM; Prins JM
    AIDS; 2008 Aug; 22(13):1583-8. PubMed ID: 18670217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structured interruptions of highly active antiretroviral therapy in cycles of 4 weeks off/12 weeks on therapy in children having a chronically undetectable viral load cause progressively smaller viral rebounds.
    Palacios GC; Sanchez LM; Briones E; Ramirez TJ; Castillo H; Rivera LG; Vazquez CA; Rodriguez-Padilla C; Holodniy M
    Int J Infect Dis; 2010 Jan; 14(1):e34-40. PubMed ID: 19467895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Morbidity, mortality, and response to treatment by children in the United Kingdom and Ireland with perinatally acquired HIV infection during 1996-2006: planning for teenage and adult care.
    Judd A; Doerholt K; Tookey PA; Sharland M; Riordan A; Menson E; Novelli V; Lyall EG; Masters J; Tudor-Williams G; Duong T; Gibb DM; ;
    Clin Infect Dis; 2007 Oct; 45(7):918-24. PubMed ID: 17806062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term effects of highly active antiretroviral therapy in pretreated, vertically HIV type 1-infected children: 6 years of follow-up.
    Resino S; Resino R; Micheloud D; Gurbindo Gutiérrez D; Léon JA; Ramos JT; Ciria L; de José I; Mellado J; Muñoz-Fernández A;
    Clin Infect Dis; 2006 Mar; 42(6):862-9. PubMed ID: 16477566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pattern and predictors of immunologic recovery in human immunodeficiency virus-infected children receiving non-nucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy.
    Puthanakit T; Kerr S; Ananworanich J; Bunupuradah T; Boonrak P; Sirisanthana V
    Pediatr Infect Dis J; 2009 Jun; 28(6):488-92. PubMed ID: 19504731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retrospective analysis of suspending HAART in selected patients with controlled HIV replication.
    Jacobs B; Neil N; Aboulafia DM
    AIDS Patient Care STDS; 2005 Jul; 19(7):429-38. PubMed ID: 16053400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV-1 viral load and CD4 cell count in untreated children with vertically acquired asymptomatic or mild disease. Paediatric European Network for Treatment of AIDS (PENTA).
    AIDS; 1998 Mar; 12(4):F1-8. PubMed ID: 9520161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of prior structured treatment interruptions on the length of time without antiretroviral treatment in chronically HIV-infected subjects.
    Moltó J; Ruiz L; Romeu J; Martínez-Picado J; Negredo E; Tural C; Sirera G; Clotet B
    AIDS Res Hum Retroviruses; 2004 Dec; 20(12):1283-8. PubMed ID: 15650419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structured intermittent interruption of chronic HIV infection treatment with highly active antiretroviral therapy: effects on leptin and TNF-alpha.
    Arjona MM; Pérez-Cano R; Garcia-Juárez R; Martín-Aspas A; del Alamo CF; Girón-González JA
    AIDS Res Hum Retroviruses; 2006 Apr; 22(4):307-14. PubMed ID: 16623632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of occasional short interruptions of HAART on the progression of HIV infection: results from a cohort study.
    Taffé P; Rickenbach M; Hirschel B; Opravil M; Furrer H; Janin P; Bugnon F; Ledergerber B; Wagels T; Sudre P;
    AIDS; 2002 Mar; 16(5):747-55. PubMed ID: 11964531
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV-1 RNA, CD4 T-lymphocytes, and clinical response to highly active antiretroviral therapy.
    Sterling TR; Chaisson RE; Moore RD
    AIDS; 2001 Nov; 15(17):2251-7. PubMed ID: 11698698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.